PDRN Injection Aftercare: What Clinicians Should Tell Patients

Aftercare is where a PDRN treatment either earns the patient's trust or quietly erodes it. The injection itself takes minutes; the week that follows is what the patient actually experiences, photographs, and talks about.

Clinics that treat aftercare as a printed sheet handed over at reception tend to see more anxious messages, more unnecessary follow-up visits, and slower rebooking. Clinics that treat it as part of the protocol — with clear expectations, defined checkpoints and a documented red-flag pathway — spend less time firefighting and more time planning the next session.

This guide sets out a practical aftercare framework for PDRN and related polynucleotide injectables: what is expected in the first 24 hours, what belongs in the first week, when a patient should be brought back, and what should be written down. It is written for clinics, distributors and brand teams working in the US market, and it deliberately avoids product-specific dosing or technique recommendations — those belong in the manufacturer's instructions for use and in the treating clinician's judgement.

One framing point before the timeline: PDRN products are not interchangeable. A salmon-derived polynucleotide injectable, a PDRN-containing skin booster and a topical PDRN serum have different risk profiles and different aftercare needs. Aftercare instructions should name the actual product the patient received.

Why Aftercare Is Part of the Treatment, Not an Add-On

Injectable aesthetic treatments produce a predictable set of local reactions: redness, swelling, tenderness, and occasionally bruising at the injection points. These are not failures of technique. They are the tissue responding to needle trauma and to the volume introduced.

The clinical risk is not the swelling itself. It is the patient misreading normal swelling as a complication, or — more seriously — dismissing an early sign of a vascular event because nobody told them what to watch for. Aftercare instructions exist to separate those two paths.

There is also a commercial argument. A patient who knows what day three will feel like is far less likely to send an alarmed message on day three. Clear expectations reduce the volume of inbound questions and make the ones that do arrive easier to triage.

Reported reactions to PDRN injections are mostly local — redness, swelling, tenderness and occasional bruising — and that set of expected reactions is what the aftercare timeline is built around.

The First 24 Hours

What Is Expected

In the first day, patients commonly report mild-to-moderate swelling at the treatment area, pinpoint bleeding that stops quickly, tenderness on touch, and a sensation of tightness. Redness may persist for several hours. Bruising, if it occurs, often appears later rather than immediately.

The pattern matters more than any single sign. Symmetrical, mildly uncomfortable swelling that peaks within 24 to 48 hours and then declines is the expected course. Swelling that is sharply one-sided, disproportionate, or accompanied by discolouration in a different area is not.

What Patients Should Avoid

The usual post-injection precautions apply, and they should be stated plainly rather than buried in a paragraph:

• Avoid strenuous exercise, saunas, steam rooms and hot yoga for the first 24 to 48 hours.

• Do not massage, press or manipulate the treated area unless the treating clinician has specifically instructed it.

• Avoid alcohol for 24 hours; it tends to increase swelling and bruising.

• Skip facials, chemical peels, laser and microneedling on the area until the clinician clears it.

• Keep the area clean and avoid makeup over injection points for the first 12 to 24 hours, or as the product's instructions state.

Two of these are routinely ignored because they sound optional: heat exposure and massage. Both increase local blood flow and both can turn a tidy result into a bruised one. Say why, not just what.

Patients often ask whether to keep using their serum, and the answer depends on how injectable and topical PDRN differ in delivery and duration, not on brand loyalty.

Days 2 to 7: Swelling, Bruising and the Recovery Curve

Bruising That Spreads

Bruising is common around the eyes, temples and jawline, where the tissue is thin and vessels are superficial. It typically darkens over 24 to 48 hours, then fades through green and yellow before resolving over one to two weeks.

Gravity-driven spread is normal and often startles patients: a bruise at the temple can appear under the eye a day later. What is not normal is a new, sharply demarcated area of blanching, mottling, or dusky discolouration that is painful out of proportion to the procedure.

When Swelling Does Not Settle

Most swelling is substantially reduced by day three to five. Persistent, firm, or increasing swelling beyond that window deserves a conversation rather than reassurance by message. So does swelling that improves and then returns.

The same applies to tenderness that escalates rather than fades, and to any area that becomes warm, hard or clearly demarcated. These are the findings that turn a routine follow-up into a clinical assessment.

Patients who are unsure whether what they are seeing is within normal limits should be able to send a photograph through a defined channel and receive a defined response time. Ad hoc WhatsApp threads are not a triage system.

The recovery curve follows what salmon-derived PDRN is doing in the tissue: an early inflammatory response, then a repair phase measured in weeks rather than days.

Weeks 2 to 4: Assessing Result and Planning the Next Session

By week two, swelling has usually resolved and the patient can judge the result on its own terms. This is the right moment for a structured review rather than a casual "how does it feel?" message.

A short review should cover four things: how the skin looks and feels relative to baseline, whether any area remains uneven or tender, whether the patient's expectations match what the product can realistically deliver, and what the next session should change, if anything.

This is also where protocols diverge. Some PDRN regimens call for a series of sessions spaced by a fixed interval; others are single treatments with maintenance. The interval should follow the product's instructions and the clinician's plan, not the clinic's calendar availability.

Patients frequently ask how many sessions they will need after the first one. Answering that honestly — as a range with conditions, not a promise — prevents the most common source of dissatisfaction: an expectation set in the treatment room that the product was never going to meet.

What the product is indicated for — skin quality, texture, hydration — matters more than the session count when PDRN for skin is discussed at the consultation.

Red Flags: When to Bring the Patient Back

Findings That Require Same-Day Review

• Severe pain that is disproportionate to the procedure and does not respond to simple analgesia.

• Blanching, mottling, or dusky and violaceous discolouration in the treated area.

• Rapidly increasing, firm swelling, particularly if asymmetric.

• Skin that becomes cool, or any reported change in vision.

• Signs of infection: spreading redness, warmth, pus, or fever.

Findings That Require Urgent Referral

Visual disturbance, severe headache, skin necrosis, or any suggestion of a vascular compromise in a high-risk area are emergencies, not aftercare questions. Every clinic should have a written escalation route — who is called, in what order, and within what time frame — and every patient-facing handout should state that the clinic must be contacted immediately if vision changes.

This is not a theoretical requirement. It is the single instruction most likely to be missing from a generic aftercare sheet, and the one with the highest consequence if it is.

Where the risk actually sits varies by category: hyaluronic acid boosters have a reversal agent, polynucleotides and peptides do not.

The Aftercare Conversation: A Simple Script

Verbal instructions delivered at the end of a treatment are poorly retained. The conversation should be short, specific and repeated in writing.

A workable structure is four sentences: what is normal today, what is normal this week, what is not normal and must be reported, and how to reach the clinic. Then hand over the written version and confirm the patient knows which product they received.

Staff who are not clinicians should be able to read that sheet aloud without improvising. If they cannot, the sheet is too long or too technical.

Front-of-house staff field those questions long before a clinician does, and the differences between HA, PDRN, PN and peptide formulations are worth knowing before the patient asks.

What to Document

Documentation is the difference between an aftercare policy and an aftercare claim. At minimum, the record should capture the product and lot, the areas treated, the volume used, the aftercare instructions issued, the date and time of any patient contact, and the clinical decision made at each follow-up.

Photographs taken under consistent lighting at baseline, day seven and week four turn vague statements into a record. They also protect the clinic when a patient's recollection of "it looked worse before" does not match the notes.

Finally, document the escalation. If a patient reported a red-flag finding, the record should show when they were seen, by whom, and what was concluded. That is what makes an aftercare protocol defensible rather than decorative.

Proof of how the PDRN was extracted and controlled is the first document to request from a supplier, and the one most buyers forget to ask for.

Aftercare When PDRN Is Combined With Other Treatments

Combination protocols are common: PDRN alongside microneedling, a laser session, or a hyaluronic acid booster. Each adds its own post-treatment response, and the aftercare instructions have to cover the combination rather than the headline product.

Two practical rules keep this manageable. First, the clinician performing the most invasive step owns the aftercare instruction for that visit. Second, the patient should leave with one sheet, not three — a single consolidated instruction is far more likely to be followed than a stack of leaflets from different products.

The order of procedures also matters. A resurfacing step performed before an injection creates a different recovery profile than the reverse, and heat-based devices raise local temperature in ways that interact with early swelling. Where protocols are staged, the aftercare timeline should be staged with them.

Staff should also be able to answer the most common combination question honestly: which part of the result came from which product. If the clinic cannot separate them, the patient will attribute everything to the injection — including the downtime.

Clinicians get asked whether current evidence supports PDRN, and the honest answer separates topical data from injectable data.

Downtime, Work and Social Plans

Patients rarely ask about swelling in the abstract. They ask whether they can attend a wedding on Saturday. Answer that question directly, with a range and a caveat, rather than with "most people are fine".

A workable default: mild redness and swelling that most patients can cover within 24 to 48 hours, visible bruising possible for up to a week in thinner-skin areas, and a result that is best judged at two to four weeks. Anything tighter than that is a promise the tissue has not agreed to.

For patients with an event inside seven days, the honest options are to treat earlier, treat less, or treat after. Saying so protects the relationship far better than a hopeful estimate that turns into a difficult conversation the morning of the event.

Skin quality changes from salmon PDRN are gradual and cumulative, which is why the four-week review matters more than the first photograph.

Conclusion: Aftercare Is a Protocol, Not a Leaflet

PDRN aftercare works when it is designed like part of the treatment: a defined timeline, a named product, a written red-flag pathway, a documented follow-up, and staff who can explain all of it in four sentences.

The clinical content of that protocol belongs with the treating clinician and the product's instructions for use. The operational content — what patients are told, when they are contacted, how concerns are triaged, what is recorded — belongs with the clinic, and it is entirely within the clinic's control.

AOWITA supplies PDRN and hyaluronic acid formulations for aesthetic clinics and brands, with batch documentation and technical information available for professional buyers. Explore the high-purity salmon PDRN HA serum or contact the team for product documentation and aftercare guidance.